Soluble VCAM-1 is known to suppress the function of α4β1 under normal physiological concentration, while in the CFS/ME patients decreased expression of CD49d/CD29 on EM CD8+ T cells may indicate reduced migration of effector cells to sites of inflammation. Here, VCAM1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.